Search Results

You are looking at 201 - 210 of 814 items for :

  • "metastases" x
  • Refine by Access: Content accessible to Me x
Clear All
Full access

James L. Mohler

large reduction in biochemical recurrence. 4 In RTOG 86-10, which evaluated RT after 3 months of ADT, the combination led to a reduction in the rates of prostate-specific antigen (PSA) failure, metastases, and cancer-specific mortality and showed a

Full access

NCCN Guidelines Insights: Cervical Cancer, Version 1.2020

Featured Updates to the NCCN Guidelines

Nadeem R. Abu-Rustum, Catheryn M. Yashar, Sarah Bean, Kristin Bradley, Susana M. Campos, Hye Sook Chon, Christina Chu, David Cohn, Marta Ann Crispens, Shari Damast, Christine M. Fisher, Peter Frederick, David K. Gaffney, Robert Giuntoli II, Ernest Han, Warner K. Huh, John R. Lurain III, Andrea Mariani, David Mutch, Christa Nagel, Larissa Nekhlyudov, Amanda Nickles Fader, Steven W. Remmenga, R. Kevin Reynolds, Rachel Sisodia, Todd Tillmanns, Stefanie Ueda, Renata Urban, Emily Wyse, Nicole R. McMillian, and Angela D. Motter

use the Silva system in clinical practice. However, the available data suggest that the system may more accurately stratify patients with HPV-related EAC by risk of metastases, recurrence, and death than the current clinicopathologic features that are

Full access

David B. Shultz, John C. Grecula, James Hayman, Maximilian Diehn, and Billy W. Loo Jr

ipsilateral hemithorax, which may include malignant pleural or pericardial effusion or hematogenous metastases (Tany,Nany,M1a/b; T3-4 because of multiple lung nodules). 10 Limited-Stage SCLC Approximately one-third of patients present with limited

Full access

Manisha H. Shah, Whitney S. Goldner, Thorvardur R. Halfdanarson, Emily Bergsland, Jordan D. Berlin, Daniel Halperin, Jennifer Chan, Matthew H. Kulke, Al B. Benson III, Lawrence S. Blaszkowsky, Jennifer Eads, Paul F. Engstrom, Paul Fanta, Thomas Giordano, Jin He, Martin J. Heslin, Gregory P. Kalemkerian, Fouad Kandeel, Sajid A. Khan, Wajih Zaheer Kidwai, Pamela L. Kunz, Boris W. Kuvshinoff II, Christopher Lieu, Venu G. Pillarisetty, Leonard Saltz, Julie Ann Sosa, Jonathan R. Strosberg, Craig A. Sussman, Nikolaos A. Trikalinos, Nataliya A. Uboha, Jonathan Whisenant, Terence Wong, James C. Yao, Jennifer L. Burns, Ndiya Ogba, and Griselda Zuccarino-Catania

studies is likely explained by a difference in the study populations—most patients enrolled in the CLARINET trial experienced stable disease in the 3 to 6 months before randomization. 10 Patients with locoregional advanced disease and/or distant metastases

Full access

Mohamad A. Hussein

lytic bone disease . Blood 2001 ; 98 : 2269 – 2271 . 17. Body JJ Greipp P Coleman RE . A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases

Full access

Kelly N. Fitzgerald and Chung-Han Lee

% (95% CI, 32%–62%) and a tolerable adverse effect profile. 28 Genetic testing can also help first-line therapy selection if it leads to clarification of RCC histologic subtype. Disease Location and Burden The distribution and size of metastases and

Full access

Stacey Shiovitz and Keith D. Eaton

Oncology (NCCN Guidelines) for NSCLC [NSCLC-11], 3 patients with oligometastatic disease, specifically a single adrenal or brain lesion, may benefit from a different treatment approach compared with those with advanced or widespread metastases (to view the

Full access

Boda Guo and Ming Liu

African American patients had roughly 3 times higher rates of papillary RCC across disease stages than non–African American patients. 3 Finally, the prognosis of RCC with lymph node metastasis is different from that with distant metastases. 4 It would

Full access

William C. Huang and Bernard H. Bochner

dissection, and bilateral uretero-enterostomy . J Urol 1950 ; 63 : 242 – 260 . 4. Mills RD Turner WH Fleischmann A . Pelvic lymph node metastases from bladder cancer: outcome in 83 patients after radical cystectomy and pelvic lymphadenectomy

Full access

Dylan Joseph Peterson, Nicolai Patrick Ostberg, Selen Bozkurt, James D. Brooks, Douglas W. Blayney, and Tina Hernandez-Boussard

preventable ED or IP visits within 180 days of starting chemotherapy (AUROC: 0.799). For this model, predictors of ED or IP visits included liver or brain metastases (ORs 1.12 and 1.07, respectively), prior ED visits (OR 1.09), white race (OR 0.90), worse